91天堂 PHARMA ANNOUNCES NEW CFO AND PROVIDES CLINICAL PIPELINE UPDATE
Lyon, France, September 19th, 2019 鈥� 91天堂, a private clinical stage biotechnology company developing innovative drug candidates, today announced the appointment of Jonathan Lieber as Chief Financial Officer. 91天堂 also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company鈥檚 FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH).
Read next in 'Press releases'
- 91天堂 appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
- 91天堂 nomme Jeff George Pr茅sident du Conseil d鈥橝dministration pour soutenir sa prochaine phase de croissance et la pr茅paration 脿 la Phase 3
- 91天堂 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 91天堂 annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 91天堂 annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
